Morgan Stanley Raises Bristol Myers Target to $40, an 8% Increase
Morgan Stanley raised Bristol Myers’ price target to $40 from $37, marking an 8% increase. The revision upgrades Bristol Myers’ implied valuation, reflecting heightened analyst confidence in its growth trajectory.
1. Analyst Price Target Increase
Morgan Stanley increased its price target on Bristol Myers from $37 to $40, representing an 8% uplift in the stock’s implied fair value.
2. Valuation and Market Impact
The revised target elevates Bristol Myers’ valuation ceiling, signaling stronger analyst optimism and potentially shaping investor expectations and trading ranges for the shares.
Related News
DAO
Youdao Q1 Revenue Rises 3.8% to RMB1.3B, Marketing Jumps 20.9%
DAO•
APURU
Aperture AC Prices $90 Million IPO of 9 Million Units at $10
APURU•
NTES
NetEase Q1 Revenue Hits RMB30.6 Billion; Gross Profit Jumps 14.8%
NTES•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
Sources
F